Multiple modes of impulsivity in parkinson's disease

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Nombela, Cristina ^a   Rittman, Timothy ^a   Robbins, Trevor W ^a,b   Rowe, James B ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; AVERSIVE BEHAVIOR; BATTERING; BEHAVIOR CHANGE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DELAY DISCOUNTING; FACTORIAL ANALYSIS; FEMALE; HUMAN; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; SELF REPORT; TEMPERAMENT;

ADULT; AGED; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; PRINCIPAL COMPONENT ANALYSIS; TASK PERFORMANCE AND ANALYSIS;

EID: 84908191517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085747     Document Type: Article

References (137)

1. Dalley JW, Everitt BJ, Robbins TW (2011) Impulsivity, compulsivity, and top-down cognitive control. Neuron 69: 680-694.
2. Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, et al. (2010) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65: 135-142.
3. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, et al. (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68: 963-968.
4. Aron AR, Durston S, Eagle DM, Logan GD, Stinear CM, et al. (2007) Converging evidence for a fronto-basal-ganglia network for inhibitory control of action and cognition. J Neurosci 27: 11860-11864. (Pubitemid 350072098)
5. Chamberlain SR, Hampshire A, Muller U, Rubia K, Del Campo N, et al. (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65: 550-555.
6. Eagle DM, Lehmann O, Theobald DE, Pena Y, Zakaria R, et al. (2009) Serotonin depletion impairs waiting but not stop-signal reaction time in rats: implications for theories of the role of 5-HT in behavioral inhibition. Neuropsychopharmacology 34: 1311-1321.
7. Klein-Flugge MC, Hunt LT, Bach DR, Dolan RJ, Behrens TE (2011) Dissociable reward and timing signals in human midbrain and ventral striatum. Neuron 72: 654-664.
8. Levy BJ, Wagner AD (2011) Cognitive control and right ventrolateral prefrontal cortex: reflexive reorienting, motor inhibition, and action updating. Ann N Y Acad Sci 1224: 40-62.
9. Aron AR, Robbins TW, Poldrack RA (2004) Inhibition and the right inferior frontal cortex. Trends Cogn Sci 8: 170-177. (Pubitemid 38429927)
10. Swick D, Ashley V, Turken AU (2008) Left inferior frontal gyrus is critical for response inhibition. BMC Neurosci 9: 102.
11. Clark L (2010) Decision-making during gambling: an integration of cognitive and psychobiological approaches. Philos Trans R Soc Lond B Biol Sci 365: 319-330.
12. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, et al. (2005) The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30: 1724-1734. (Pubitemid 43090698)
13. Macoveanu J, Rowe JB, Hornboll B, Elliott R, Paulson OB, et al. (2012) Playing it safe but losing anyway-Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur Neuropsychopharmacol.
14. Eagle DM, Bari A, Robbins TW (2008) The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) 199: 439-456.
15. Schultz W (2001) Reward signaling by dopamine neurons. Neuroscientist 7: 293-302.
16. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD (2006) Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442: 1042-1045. (Pubitemid 44330261)
17. Potenza MN, Voon V, Weintraub D (2007) Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 3: 664-672. (Pubitemid 350238058)
18. Chamberlain SR, Fineberg NA, Blackwell AD, Clark L, Robbins TW, et al. (2007) A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 45: 654-662. (Pubitemid 46001411)
19. Robinson ES, Eagle DM, Mar AC, Bari A, Banerjee G, et al. (2008) Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 33: 1028-1037. (Pubitemid 351367544)
20. Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ (2006) Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry 163: 1282-1284. (Pubitemid 44464460)
21. Winstanley CA, Eagle DM, Robbins TW (2006) Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev 26: 379-395.
22. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, et al. (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63: 969-973. (Pubitemid 44036299)
23. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65: 1570-1574. (Pubitemid 41689470)
24. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, et al. (2009) Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 8: 1140-1149.
25. Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, et al. (2009) Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol 66: 817-824.
26. Frank MJ, Samanta J, Moustafa AA, Sherman SJ (2007) Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 318: 1309-1312. (Pubitemid 350172897)
27. Obeso I, Wilkinson L, Casabona E, Bringas ML, Alvarez M, et al. (2011) Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res 212: 371-384.
28. Gauggel S, Rieger M, Feghoff TA (2004) Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 75: 539-544. (Pubitemid 38406648)
29. Kobayakawa M, Koyama S, Mimura M, Kawamura M (2008) Decision making in Parkinson's disease: Analysis of behavioral and physiological patterns in the Iowa gambling task. Mov Disord 23: 547-552.
30. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, et al. (2002) Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 40: 2257-2267. (Pubitemid 35303365)
31. Cools R, Barker RA, Sahakian BJ, Robbins TW (2003) L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41: 1431-1441. (Pubitemid 36808816)
32. Rivaud-Pechoux S, Vidailhet M, Brandel JP, Gaymard B (2007) Mixing pro-and antisaccades in patients with parkinsonian syndromes. Brain 130: 256-264. (Pubitemid 46026240)
33. Koch G, Costa A, Brusa L, Peppe A, Gatto I, et al. (2008) Impaired reproduction of second but not millisecond time intervals in Parkinson's disease. Neuropsychologia 46: 1305-1313.
34. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909. (Pubitemid 37130207)
35. Biundo R, Formento-Dojot P, Facchini S, Vallelunga A, Ghezzo L, et al. (2011) Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. J Neurol Sci 310: 64-69.
36. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, et al. (2011) Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 18: 703-710.
37. Cumming P, Borghammer P (2012) Molecular imaging and the neuropathologies of Parkinson's disease. Curr Top Behav Neurosci 11: 117-148.
38. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321-328. (Pubitemid 13004530)
39. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 510: 104-107. (Pubitemid 20060808)
40. Politis M, Wu K, Loane C, Kiferle L, Molloy S, et al. (2010) Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40: 216-221.
41. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT (2004) Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127: 791-800. (Pubitemid 38478524)
42. Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, et al. (2010) The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiol Aging 31: 1064-1068.
43. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752.
44. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
45. Beck ATGM (1988) Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. cLIN pSYCHOL rEV 8: 77-102.
46. Brodsky MA, Godbold J, Roth T, Olanow CW (2003) Sleepiness in Parkinson's disease: a controlled study. Mov Disord 18: 668-672. (Pubitemid 36790282)
47. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
48. Fahn SE, R.; atmotUPsDRSD C. (1987) Unified Parkinson's Disease Rating Scale. In: Fahn SM, C., Calne, D., editor. Recent developments in Parkinson's disease. New York: MacMillan. pp. 153-163.
49. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21: 1078-1085. (Pubitemid 44762726)
50. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW (2003) Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 6: 115-116. (Pubitemid 36182778)
51. Rakitin BC, Gibbon J, Penney TB, Malapani C, Hinton SC, et al. (1998) Scalar expectancy theory and peak-interval timing in humans. J Exp Psychol Anim Behav Process 24: 15-33. (Pubitemid 128738256)
52. Penny WD, Roberts SJ, Curran EA, Stokes MJ (2000) EEG-based communication: a pattern recognition approach. IEEE Trans Rehabil Eng 8: 214-215. (Pubitemid 30437018)
53. Penney TB, Gibbon J, Meck WH (2000) Differential effects of auditory and visual signals on clock speed and temporal memory. J Exp Psychol Hum Percept Perform 26: 1770-1787.
54. Allman MJ, Meck WH (2012) Pathophysiological distortions in time perception and timed performance. Brain 135: 656-677.
55. Bouvard M, Sigel L, Laurent A (2012) [A study of temperament and personality in children diagnosed with attention-deficit hyperactivity disorder (ADHD)]. Encephale 38: 418-425.
56. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, et al. (2013) The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry 84: 544-551.
57. Wolters E, van der Werf YD, van den Heuvel OA (2008) Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol 255 Suppl 5: 48-56.
58. Ceravolo R, Frosini D, Rossi C, Bonuccelli U (2009) Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 15 Suppl 4: S111-115.
59. Djamshidian A, O'Sullivan SS, Wittmann BC, Lees AJ, Averbeck BB (2011) Novelty seeking behaviour in Parkinson's disease. Neuropsychologia 49: 2483-2488.
60. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, et al. (2009) Fifty years of the Barratt Impulsiveness Scale: An update and review. Personality and Individual Differences 47: 385-395.
61. Durana J, Barnes D (1993) A neurodivelopment view of impulsivity and its relationship to the superfactors of personality. In: MCcrown W, Johnson J, Shur M, editors. The impulsive Client: Theory, Research and Treatment. Washington: American Psychological Association.
62. Broos N, Schmaal L, Wiskerke J, Kostelijk L, Lam T, et al. (2012) The relationship between impulsive choice and impulsive action: a cross-species translational study. PLoS One 7: e36781.
63. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA (2010) Deep brain stimulation: from neurology to psychiatry? Trends Neurosci 33: 474-484.
64. Lee MS, Lyoo CH, Ryu YH, Lim HS, Nam CM, et al. (2011) The effect of age on motor deficits and cerebral glucose metabolism of Parkinson's disease. Acta Neurol Scand 124: 196-201.
65. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, et al. (2012) White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 62: 1675-1684.
66. Barch DM, Braver TS, Akbudak E, Conturo T, Ollinger J, et al. (2001) Anterior cingulate cortex and response conflict: effects of response modality and processing domain. Cereb Cortex 11: 837-848. (Pubitemid 32800551)
67. Burrell JR, Hornberger M, Carpenter RH, Kiernan MC, Hodges JR (2012) Saccadic abnormalities in frontotemporal dementia. Neurology 78: 1816-1823.
68. Takeuchi H, Taki Y, Sassa Y, Hashizume H, Sekiguchi A, et al. (2012) Regional gray and white matter volume associated with Stroop interference: evidence from voxel-based morphometry. Neuroimage 59: 2899-2907.
69. Ghosh BC, Calder AJ, Peers PV, Lawrence AD, Acosta-Cabronero J, et al. (2012) Social cognitive deficits and their neural correlates in progressive supranuclear palsy. Brain 135: 2089-2102.
70. Whelan R, Conrod PJ, Poline JB, Lourdusamy A, Banaschewski T, et al. (2012) Adolescent impulsivity phenotypes characterized by distinct brain networks. Nat Neurosci 15: 920-925.
71. Bari A, Eagle DM, Mar AC, Robinson ES, Robbins TW (2009) Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl) 205: 273-283.
72. Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, et al. (2012) Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci 32: 7316-7324.
73. Frank MJ (2005) Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cogn Neurosci 17: 51-72.
74. Eagle DM, Wong JC, Allan ME, Mar AC, Theobald DE, et al. (2011) Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. J Neurosci 31: 7349-7356.
75. Obeso VT, Gordon DL, Issenberg SB, Baker JW, Clark RG, et al. (2005) A multicenter study to provide evidence of construct validity in a computer-based outcome measure of neurology clinical skills. Acad Med 80: S71-74. (Pubitemid 41383279)
76. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008) Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 172: 45-71.
77. Olijslagers JE, Werkman TR, McCreary AC, Kruse CG, Wadman WJ (2006) Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action. Curr Neuropharmacol 4: 59-68.
78. Perbal S, Deweer B, Pillon B, Vidailhet M, Dubois B, et al. (2005) Effects of internal clock and memory disorders on duration reproductions and duration productions in patients with Parkinson's disease. Brain Cogn 58: 35-48. (Pubitemid 40692877)
79. Voon V, Mehta AR, Hallett M (2011) Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol 24: 324-330.
80. Karalunas SL, Huang-Pollock CL (2011) Examining relationships between executive functioning and delay aversion in attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol 40: 837-847.
81. Bechara A, Damasio AR, Damasio H, Anderson SW (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50: 7-15.
82. Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, et al. (2010) Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl) 207: 645-659.
83. Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, et al. (2006) Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 31: 651-658. (Pubitemid 43276981)
84. Coull JT, Cheng RK, Meck WH (2011) Neuroanatomical and neurochemical substrates of timing. Neuropsychopharmacology 36: 3-25.
85. Meck WH (1996) Neuropharmacology of timing and time perception. Brain Res Cogn Brain Res 3: 227-242.
86. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, et al. (1999) Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 122 (Pt 9): 1637-1650. (Pubitemid 29425668)
87. Carpenter RH, Williams ML (1995) Neural computation of log likelihood in control of saccadic eye movements. Nature 377: 59-62.
88. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA (2007) Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 27: 4832-4838. (Pubitemid 46699066)
89. Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, et al. (2008) Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 131: 2094-2105.
90. Milenkova M, Mohammadi B, Kollewe K, Schrader C, Fellbrich A, et al. (2011) Intertemporal choice in Parkinson's disease. Mov Disord 26: 2004-2010.
91. Altmann LJ, Troche MS (2011) High-level language production in Parkinson's disease: a review. Parkinsons Dis 2011: 238956.
92. Clark L, Robbins TW, Ersche KD, Sahakian BJ (2006) Reflection impulsivity in current and former substance users. Biol Psychiatry 60: 515-522. (Pubitemid 44292153)
93. Barker RA, Michell AW (2009) "The eyes have it". Saccadometry and Parkinson's disease. Exp Neurol 219: 382-384.
94. Perneczky R, Ghosh BC, Hughes L, Carpenter RH, Barker RA, et al. (2011) Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. Neurobiol Dis 43: 79-85.
95. Kim JO, Mueller C.V. (1978) Introduction to factor analysis: What it is and how to do it. Beverly Hills, CA: Sage.
96. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 26: 399-406.
97. Sugden C, Housden CR, Aggarwal R, Sahakian BJ, Darzi A (2012) Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann Surg 255: 222-227.
98. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E, et al. (2009) Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 16: 493-497.
99. Brambilla F, Dalle Grave R, Calugi S, Marchesini G, Baroni S, et al. (2010) Effects of cognitive-behavioral therapy on Eating Disorders: neurotransmitter secretory response to treatment. Psychoneuroendocrinology 35: 729-737.
100. Marazziti D, Masala I, Baroni S, Polini M, Massimetti G, et al. (2010) Male axillary extracts modify the affinity of the platelet serotonin transporter and impulsiveness in women. Physiol Behav 100: 364-368.
101. Djamshidian A, O'Sullivan SS, Lees A, Averbeck BB (2011) Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat Disord 17: 212-214.
102. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, et al. (2006) Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67: 415-420.
103. Boggio PS, Fregni F, Bermpohl F, Mansur CG, Rosa M, et al. (2005) Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov Disord 20: 1178-1184. (Pubitemid 41632205)
104. Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, et al. (2007) Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease. Brain Res Bull 74: 75-83. (Pubitemid 47187915)
105. Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser JP (2010) Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 35: 2155-2164.
106. Mobini S, Chiang TJ, Al-Ruwaitea AS, Ho MY, Bradshaw CM, et al. (2000) Effect of central 5-hydroxytryptamine depletion on inter-temporal choice: a quantitative analysis. Psychopharmacology (Berl) 149: 313-318. (Pubitemid 30262346)
107. Nakahara H, Kaveri S (2010) Internal-time temporal difference model for neural value-based decision making. Neural Comput 22: 3062-3106.
108. Peters J, Buchel C (2011) The neural mechanisms of inter-temporal decision-making: understanding variability. Trends Cogn Sci 15: 227-239.
109. Antonelli F, Ray N, Strafella AP (2011) Impulsivity and Parkinson's disease: more than just disinhibition. J Neurol Sci 310: 202-207.
110. Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, et al. (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 41: 2361-2373.
111. O'Callaghan C, Naismith SL, Hodges JR, Lewis SJ, Hornberger M (2012) Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. Cortex.
112. Lord S, Baker K, Nieuwboer A, Burn D, Rochester L (2011) Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol 258: 566-572.
113. Raust A, Slama F, Mathieu F, Roy I, Chenu A, et al. (2007) Prefrontal cortex dysfunction in patients with suicidal behavior. Psychol Med 37: 411-419.
114. Nathaniel-James DA, Fletcher P, Frith CD (1997) The functional anatomy of verbal initiation and suppression using the Hayling Test. Neuropsychologia 35: 559-566. (Pubitemid 27144007)
115. Bari A, Robbins TW (2013) Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology (Berl) 230: 89-111.
116. Bari A, Mar AC, Theobald DE, Elands SA, Oganya KC, et al. (2011) Prefrontal and monoaminergic contributions to stop-signal task performance in rats. J Neurosci 31: 9254-9263.
117. Overtoom CC, Bekker EM, van der Molen MW, Verbaten MN, Kooij JJ, et al. (2009) Methylphenidate restores link between stop-signal sensory impact and successful stopping in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 65: 614-619.
118. Isaias IU, Siri C, Cilia R, De Gaspari D, Pezzoli G, et al. (2008) The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 23: 411-415.
119. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, et al. (2011) Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov Disord 26: 464-468.
120. Cools R, Blackwell A, Clark L, Menzies L, Cox S, et al. (2005) Tryptophan depletion disrupts the motivational guidance of goal-directed behavior as a function of trait impulsivity. Neuropsychopharmacology 30: 1362-1373. (Pubitemid 40848090)
121. Cherbuin N, Windsor TD, Anstey KJ, Maller JJ, Meslin C, et al. (2008) Hippocampal volume is positively associated with behavioural inhibition (BIS) in a large community-based sample of mid-life adults: the PATH through life study. Soc Cogn Affect Neurosci 3: 262-269.
122. Cools R, Barker RA, Sahakian BJ, Robbins TW (2003) l-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 41: 1431-1441. (Pubitemid 36808816)
123. Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F (2010) Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 25: 1994-1995.
124. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, et al. (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65: 1604-1611.
125. Buhusi CV, Meck WH (2007) Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps. Behav Processes 74: 159-167. (Pubitemid 46215909)
126. Jones CR, Rosenkranz K, Rothwell JC, Jahanshahi M (2004) The right dorsolateral prefrontal cortex is essential in time reproduction: an investigation with repetitive transcranial magnetic stimulation. Exp Brain Res 158: 366-372. (Pubitemid 39304302)
127. Zapata MA, Torres de GY, Montoya LP (2011) [Risk of pathological gambling, Associated factors and mental disorders in youth from Medellin - Colombia]. Adicciones 23: 17-25.
128. Marazziti D, Golia F, Picchetti M, Pioli E, Mannari P, et al. (2008) Decreased density of the platelet serotonin transporter in pathological gamblers. Neuropsychobiology 57: 38-43.
129. Temel Y, Visser-Vandewalle V, Carpenter RH (2009) Saccadometry: a novel clinical tool for quantification of the motor effects of subthalamic nucleus stimulation in Parkinson's disease. Exp Neurol 216: 481-489.
130. Kirby KN, Marakovic NN (1996) Delay-discounting probabilistic rewards: Rates decrease as amounts increase. Psychon Bull Rev 3: 100-104. (Pubitemid 126421503)
131. Barrat ES (1959) Anxiety and impulsiveness related to psychomotor efficiency Perceptual and Motor Skills 9: 191-198.
132. Carver CSW, T.L. (1994) Impulsiveness and aggression. In: Monahan JS, H J., editor. Violence and mental disorder: Developments in risk assessment. Chicago: University of Chicago Press. pp. 61-80.
133. Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144: 1184-1188. (Pubitemid 17147523)
134. Grant JE (2008) Impulse Control Disorders: A Clinician's Guide to Understanding and Treating Behavioral Addictions. New York: WW Norton and Company.
135. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55: 1621-1626.
136. Burgess PWS, T. (1997) The Hayling and Brixton tests. Bury St. Edmunds, UK: Thames Valley Test Company.
137. Stroop JR (1935) Studies of interference in serial verbal reactions. Journal of Experimental Psychology 18: 643-662.